Cargando…
High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases
PURPOSE: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma. PATIENTS AND METHODS: We collected clinical and pathological data of 41 cases of newly...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082796/ https://www.ncbi.nlm.nih.gov/pubmed/32214848 http://dx.doi.org/10.2147/CMAR.S243753 |
_version_ | 1783508417103527936 |
---|---|
author | Li, Jiayin Liu, Xiaoyin Yao, Zhihua Zhang, Mingzhi |
author_facet | Li, Jiayin Liu, Xiaoyin Yao, Zhihua Zhang, Mingzhi |
author_sort | Li, Jiayin |
collection | PubMed |
description | PURPOSE: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma. PATIENTS AND METHODS: We collected clinical and pathological data of 41 cases of newly diagnosed HGBL, NOS, and analyzed diagnosis, prognosis and treatment to examine progression-free survival (PFS) and overall survival (OS). RESULTS: Among the 41 cases studied, the median PFS was 6.0 months and the median OS was 18.0 months. Compared with patients treated with the R-CHOP regimen, patients treated with a high-intensity chemotherapy (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS (PFS: χ(2)=4.173, P=0.041; OS: χ(2)=5.200, P=0.023). A subgroup analysis showed that the OS for the double-expressor lymphoma (DEL) was inferior to that for the non-DEL (χ(2)=4.563, P=0.033), and this trend was also seen for the single-hit lymphoma with MYC rearrangement (SHL) and the non-SHL (χ(2)=4.955, P=0.026). Patients with low International Prognostic Index (IPI) scores (≤2) had better survival rates than those with high scores (>2) (PFS: χ(2)=6.482, P=0.011; OS: χ(2)=10.156, P=0.001). CONCLUSION: HGBL, NOS is associated with a high degree of malignancy, short survival period, and substantial extranodal involvement. High-intensity chemotherapy may improve patient prognosis. While IPI scores statistically correlated with the prognosis, SHL and DEL correlated with an inferior survival rate. New and improved treatments will be needed for HGBL, NOS. |
format | Online Article Text |
id | pubmed-7082796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70827962020-03-25 High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases Li, Jiayin Liu, Xiaoyin Yao, Zhihua Zhang, Mingzhi Cancer Manag Res Original Research PURPOSE: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma. PATIENTS AND METHODS: We collected clinical and pathological data of 41 cases of newly diagnosed HGBL, NOS, and analyzed diagnosis, prognosis and treatment to examine progression-free survival (PFS) and overall survival (OS). RESULTS: Among the 41 cases studied, the median PFS was 6.0 months and the median OS was 18.0 months. Compared with patients treated with the R-CHOP regimen, patients treated with a high-intensity chemotherapy (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS (PFS: χ(2)=4.173, P=0.041; OS: χ(2)=5.200, P=0.023). A subgroup analysis showed that the OS for the double-expressor lymphoma (DEL) was inferior to that for the non-DEL (χ(2)=4.563, P=0.033), and this trend was also seen for the single-hit lymphoma with MYC rearrangement (SHL) and the non-SHL (χ(2)=4.955, P=0.026). Patients with low International Prognostic Index (IPI) scores (≤2) had better survival rates than those with high scores (>2) (PFS: χ(2)=6.482, P=0.011; OS: χ(2)=10.156, P=0.001). CONCLUSION: HGBL, NOS is associated with a high degree of malignancy, short survival period, and substantial extranodal involvement. High-intensity chemotherapy may improve patient prognosis. While IPI scores statistically correlated with the prognosis, SHL and DEL correlated with an inferior survival rate. New and improved treatments will be needed for HGBL, NOS. Dove 2020-03-13 /pmc/articles/PMC7082796/ /pubmed/32214848 http://dx.doi.org/10.2147/CMAR.S243753 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Jiayin Liu, Xiaoyin Yao, Zhihua Zhang, Mingzhi High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title | High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title_full | High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title_fullStr | High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title_full_unstemmed | High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title_short | High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases |
title_sort | high-grade b-cell lymphomas, not otherwise specified: a study of 41 cases |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082796/ https://www.ncbi.nlm.nih.gov/pubmed/32214848 http://dx.doi.org/10.2147/CMAR.S243753 |
work_keys_str_mv | AT lijiayin highgradebcelllymphomasnototherwisespecifiedastudyof41cases AT liuxiaoyin highgradebcelllymphomasnototherwisespecifiedastudyof41cases AT yaozhihua highgradebcelllymphomasnototherwisespecifiedastudyof41cases AT zhangmingzhi highgradebcelllymphomasnototherwisespecifiedastudyof41cases |